Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Update on Glycosphingolipids Abundance in Hepatocellular Carcinoma

Version 1 : Received: 22 March 2022 / Approved: 23 March 2022 / Online: 23 March 2022 (04:39:25 CET)

A peer-reviewed article of this Preprint also exists.

Byrne, F.L.; Olzomer, E.M.; Lolies, N.; Hoehn, K.L.; Wegner, M.-S. Update on Glycosphingolipids Abundance in Hepatocellular Carcinoma. Int. J. Mol. Sci. 2022, 23, 4477. Byrne, F.L.; Olzomer, E.M.; Lolies, N.; Hoehn, K.L.; Wegner, M.-S. Update on Glycosphingolipids Abundance in Hepatocellular Carcinoma. Int. J. Mol. Sci. 2022, 23, 4477.

Journal reference: Int. J. Mol. Sci. 2022, 23, 4477
DOI: 10.3390/ijms23094477

Abstract

Hepatocellular carcinoma (HCC) is the most frequent type of primary liver cancer. Low numbers of HCC patients being suitable for liver resection or transplantation and multidrug resistance development during pharmacotherapy leads to high death rates for HCC patients. Understanding the molecular mechanisms of HCC aetiology contributes to development of novel therapeutic strategies for prevention and treatment of HCC. UDP-glucose ceramide glycosyltransferase (UGCG), a key enzyme in glycosphingolipid metabolism, generates glucosylceramide (GlcCer), which is the precursor for all glycosphingolipids (GSLs). Since UGCG gene expression is altered in 0.8 % of HCC tumors, GSLs may play a role in cellular processes in liver cancer cells. Here, we discuss current literature about GSLs and their abundance in normal liver cells, Gaucher disease and HCC. Furthermore, we review the involvement of UGCG/GlcCer in multidrug resistance development, globosides as a potential prognostic marker for HCC, gangliosides as a potential liver cancer stem cell marker, and the role of sulfatides in tumor metastasis. Only a limited number of molecular mechanisms executed by GSLs in HCC are known, which we summarize here briefly.

Keywords

glycolysis; GEMs; oxidative phosphorylation; UGCG; glucosylceramide; normal liver cells; gangliosides; lacto/neo-lacto series GSLs; sulfatides

Subject

MEDICINE & PHARMACOLOGY, Oncology & Oncogenics

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.

We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.